نتایج جستجو برای: eluting stents treatment failure myocardial infarction

تعداد نتایج: 1845761  

Journal: :World journal of emergency medicine 2014
Hai-Mu Yao Tong-Wen Sun You-Dong Wan Xiao-Juan Zhang Xin Fu De-Liang Shen Jin-Ying Zhang Ling Li

BACKGROUND The application of coronary stents, especially drug-eluting stents (DESs), has made percutaneous coronary intervention (PCI) one of important therapeutic methods for CHD. DES has reduced the in-stent restenosis to 5%-9% and significantly improved the long-term prognosis of patients with CHD. The study aimed to investigate the long-term efficacy and safety of domestic drug-eluting ste...

Journal: :JAMA 2005
Adnan Kastrati Alban Dibra Sonja Eberle Julinda Mehilli José Suárez de Lezo Jean-Jacque Goy Kurt Ulm Albert Schömig

CONTEXT Placement of sirolimus-eluting stents or paclitaxel-eluting stents has emerged as the predominant percutaneous treatment strategy in patients with coronary artery disease (CAD). Whether there are any differences in efficacy and safety between these 2 drug-eluting stents is unclear. OBJECTIVE To compare outcomes of sirolimus-eluting and paclitaxel-eluting coronary stents on the basis o...

Journal: :Lancet 2004
Mohan N Babapulle Lawrence Joseph Patrick Bélisle James M Brophy Mark J Eisenberg

BACKGROUND Drug-eluting stents (DES) are associated with lower restenosis rates than bare-metal stents (BMS), but the benefits and safety of the new devices have not been systematically quantified across different trials. We undertook a meta-analysis of randomised trials comparing BMS and stents eluting sirolimus or paclitaxel. METHODS A systematic literature search aimed to identify all rand...

2011
aarten A. Vink Maurits T. Dirksen Gerrit J. Laarman

ackground In primary percutaneous coronary intervention for acute ST-segment elevation myocarial infarction (STEMI), the use of drug-eluting stents (DES) is still controversial. Several randomized ontrolled trials of DES, compared with bare-metal stents (BMS), with short-term follow-up showed a eduction in target lesion revascularization (TLR), but no differences in rates of cardiac death or re...

2012
Marco Valgimigli Monia Monti Antonella Scalone

Background—The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration–approved drug-eluting or bare-metal ...

2010
Erik H. Middlebrooks Mukta Panda

The antiphospholipid syndrome (APS) is a common cause of both arterial and venous thrombosis. While studies exist demonstrating the role of APS in coronary artery bypass graft failure, its role in stent thrombosis is less clearly documented. Also, a literature search of PubMed did not reveal any articles regarding the coexistence of clopidogrel resistance and APS despite increasing awareness of...

Journal: :Journal of interventional cardiology 2012
Mohamed Abdel-Wahab Christoph A Nienaber Ahmad E Mostafa Miroslaw Ferenc Sigmund Silber Georg Sabin Ulrich Tebbe Ibrahim Akin Matthias Hochadel Jochen Senges Karl-Heinz Kuck Gert Richardt

BACKGROUND Controversy exists about the impact of treating bifurcations on overall outcome of coronary interventions using drug-eluting stents (DES). We sought to investigate 1-year outcome of the treatment of bifurcation lesions using DES in a large "real-world" cohort. METHODS AND RESULTS Among 5,126 patients enrolled in phase I of the multicenter German Drug-Eluting Stent Registry, 814 (16...

2010
Taufiek K Rajab Zain Khalpey Bernhard Kraemer Frederic S Resnic Robert P Gallegos

Coronary artery dissection is a rare but well-described cause for myocardial infarction during the post-partum period. Dissection of multiple coronary arteries is even less frequent. Here we present a case of recurrent post-partum coronary artery dissections. This unusual presentation poses unique problems for management. A 35 year-old female, gravida 3 para 2, presented with myocardial infarct...

Journal: :Circulation 2006
Myeong-Ki Hong Gary S Mintz Cheol Whan Lee Duk-Woo Park Kyoung-Min Park Bong-Ki Lee Young-Hak Kim Jong-Min Song Ki-Hoon Han Duk-Hyun Kang Sang-Sig Cheong Jae-Kwan Song Jae-Joong Kim Seong-Wook Park Seung-Jung Park

BACKGROUND Late stent malapposition (LSM) after drug-eluting stent (DES) implantation has not been evaluated sufficiently in real-world practice. METHODS AND RESULTS We evaluated the incidence, mechanisms, predictors, and long-term prognosis of LSM after DES implantation in 557 patients (705 native lesions; sirolimus-eluting stent in 538 lesions and paclitaxel-eluting stent in 167 lesions) in...

Journal: :Circulation 2012
Marco Valgimigli Gianluca Campo Monia Monti Pascal Vranckx Gianfranco Percoco Carlo Tumscitz Fausto Castriota Federico Colombo Matteo Tebaldi Giuseppe Fucà Moh'd Kubbajeh Elisa Cangiano Monica Minarelli Antonella Scalone Caterina Cavazza Alice Frangione Marco Borghesi Jlenia Marchesini Giovanni Parrinello Roberto Ferrari

BACKGROUND The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید